152 related articles for article (PubMed ID: 31264053)
21. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography.
Yamashita K; Yoshiura T; Hiwatashi A; Togao O; Yoshimoto K; Suzuki SO; Abe K; Kikuchi K; Maruoka Y; Mizoguchi M; Iwaki T; Honda H
Neuroradiology; 2013 Feb; 55(2):135-43. PubMed ID: 22961074
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis.
Kawai N; Nishiyama Y; Miyake K; Tamiya T; Nagao S
Ann Nucl Med; 2005 Dec; 19(8):685-90. PubMed ID: 16444994
[TBL] [Abstract][Full Text] [Related]
23. Enhanced MRI and 18F-FDG PET/CT Findings of Primary Central Nervous System Lymphoma Mimicking Encephalitis.
Ge J; Zuo C; Guan Y; Zhao G
Clin Nucl Med; 2016 Oct; 41(10):e436-8. PubMed ID: 27355853
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
[TBL] [Abstract][Full Text] [Related]
25.
Kong Z; Jiang C; Zhu R; Feng S; Wang Y; Li J; Chen W; Liu P; Zhao D; Ma W; Wang Y; Cheng X
Neuroimage Clin; 2019; 23():101912. PubMed ID: 31491820
[TBL] [Abstract][Full Text] [Related]
26. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204
[TBL] [Abstract][Full Text] [Related]
27. Case report of an elderly woman with atypical imaging for primary central nervous system lymphoma who needed a brain biopsy for diagnosis.
Matsuzono K; Yagisawa T; Ohtani K; Ishishita Y; Yamaguchi T; Mashiko T; Ozawa T; Koide R; Tanaka R; Kawai K; Fujimoto S
J Int Med Res; 2021 Aug; 49(8):3000605211035197. PubMed ID: 34461767
[TBL] [Abstract][Full Text] [Related]
28. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation?
Purandare NC; Puranik A; Shah S; Agrawal A; Gupta T; Moiyadi A; Shetty P; Shridhar E; Jalali R; Rangarajan V
Nucl Med Commun; 2017 Dec; 38(12):1109-1116. PubMed ID: 28922334
[TBL] [Abstract][Full Text] [Related]
29. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
30. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
[TBL] [Abstract][Full Text] [Related]
31. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
Rosenfeld SS; Hoffman JM; Coleman RE; Glantz MJ; Hanson MW; Schold SC
J Nucl Med; 1992 Apr; 33(4):532-6. PubMed ID: 1552337
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
Zhang Q; Tian T; Wang L; Qiu H; Li D
Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
[TBL] [Abstract][Full Text] [Related]
33. [Manifestations of PET/CT Imaging in Primary Central Nervous System Lymphoma].
Yin L; Lin ZC; Yue JL; Huang SM; Chen W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1416-1420. PubMed ID: 27784367
[TBL] [Abstract][Full Text] [Related]
34. Low ADC in CNS Lymphoma.
Pyatigorskaya N; Galanaud D; Dormont D; Soussain C; Kas A
Clin Nucl Med; 2020 Jul; 45(7):545-546. PubMed ID: 32404710
[TBL] [Abstract][Full Text] [Related]
35. A False-Negative Case of Primary Central Nervous System Lymphoma on 11C-Methionine PET and Intense 18F-FDG Uptake.
García-Garzon JR; Villasboas-Rosciolesi D; Baquero M; Bassa P; Soler M; Riera E
Clin Nucl Med; 2016 Aug; 41(8):664-5. PubMed ID: 27187734
[TBL] [Abstract][Full Text] [Related]
36. Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients.
Cheng G; Zhang J
Neurol Sci; 2019 Mar; 40(3):535-542. PubMed ID: 30580380
[TBL] [Abstract][Full Text] [Related]
37. Distinguishing between primary central nervous system lymphoma and glioblastoma using [18F]fluoromisonidazole and [18F]FDG PET.
Uchinomura S; Mitamura K; Norikane T; Yamamoto Y; Oishi A; Hatakeyama T; Miyake K; Nishiyama Y
Nucl Med Commun; 2022 Mar; 43(3):270-274. PubMed ID: 34864812
[TBL] [Abstract][Full Text] [Related]
38. Utility of brain FDG-PET in primary CNS lymphoma.
Mohile NA; Deangelis LM; Abrey LE
Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
[TBL] [Abstract][Full Text] [Related]
39. Interim
Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Park CS; Kim JH; Lee SW; Suh C
Ann Hematol; 2017 Sep; 96(9):1509-1515. PubMed ID: 28725988
[No Abstract] [Full Text] [Related]
40. 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma.
Kasenda B; Haug V; Schorb E; Fritsch K; Finke J; Mix M; Hader C; Weber WA; Illerhaus G; Meyer PT
J Nucl Med; 2013 Feb; 54(2):184-91. PubMed ID: 23249539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
